Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Cancer Invest. 2021 Sep;39(8):645-652. doi: 10.1080/07357907.2021.1948563. Epub 2021 Jul 14.
The aim of the study was to report long-term results of intensity-modulated radiotherapy for patients with T4 classification nasopharyngeal carcinoma (NPC). From September 2007 to January 2013, 155 patients were retrospectively analyzed. The estimated 10-year local recurrent-free survival (LRFS), regional recurrent-free survival (RRFS), distant metastasis-free survival (DMFS), and overall survival (OS) rates were 79.4%, 93.2%, 69.0%, and 54.2%, respectively. Cycle number of chemotherapy was a significant predictor of LRFS, OS, and progression-free survival. There was no significant difference in survival rates between patients treated with induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) and patients with IC plus IMRT and adjuvant chemotherapy (AC).
本研究旨在报告 T4 期鼻咽癌患者调强放疗的长期结果。回顾性分析了 2007 年 9 月至 2013 年 1 月的 155 例患者。10 年局部无复发生存率(LRFS)、区域无复发生存率(RRFS)、无远处转移生存率(DMFS)和总生存率(OS)分别为 79.4%、93.2%、69.0%和 54.2%。化疗周期数是 LRFS、OS 和无进展生存率的显著预测因素。接受诱导化疗(IC)加同期放化疗(CCRT)和 IC 加调强放疗和辅助化疗(AC)的患者的生存率无显著差异。